BLLN · NASDAQ
BillionToOne, Inc.
$113.00 +2.63 (+2.38%)
Company overview
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides a molecular counting platform designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations present in the tumor, including deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NASDAQ
- Market cap
- $5.3B
- Employees
- 620
- Headquarters
- Menlo Park, CA
- Website
- billiontoone.com
- CEO
- Oguzhan Atay
- Listed
- November 6, 2025
- P/E
- 219.59
- Dividend yield
- 0.00%
Company financials
- Revenue
- $355M
- Gross profit
- $250M
- Operating income
- $36.2M
- EBITDA
- $41.3M
- Net income
- $25.2M
- EPS
- $0.51
- Total assets
- $701M
- Total debt
- $144M
- Gross margin
- 70.40%
- Net margin
- 7.11%
- Earnings yield
- 0.46%
No annual segmentation.
No geographic segmentation.
BLLN
1D
NASDAQ
O110.63H113.42L109.56C110.45+0.04 (+0.04%)Vol360.37K
News